Last 7 days
-10.2%
Last 30 days
-15.8%
Last 90 days
-3.2%
Trailing 12 Months
15.6%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 404.8B | 94.9B | -5.16% | -10.64% | 22.56 | 4.26 | 1.25% | -14.07% |
LLY | 296.8B | 28.5B | -5.67% | 20.74% | 47.53 | 10.4 | 0.79% | 11.88% |
MRK | 272.8B | 59.3B | -1.75% | 40.02% | 17.88 | 4.63 | 21.72% | 11.27% |
PFE | 226.4B | 100.3B | -8.43% | -20.95% | 7.22 | 2.26 | 23.43% | 42.74% |
BMY | 142.7B | 46.2B | -7.78% | -1.12% | 22.55 | 3.09 | -0.49% | -9.54% |
MID-CAP | ||||||||
PRGO | 4.8B | 4.5B | -0.20% | -5.41% | -34.17 | 1.08 | 7.56% | -104.06% |
RETA | 3.3B | 2.2M | 105.10% | 171.03% | -10.52 | 1.5K | -80.71% | -4.88% |
SMALL-CAP | ||||||||
SUPN | 1.9B | 667.2M | -9.96% | 17.66% | 31.57 | 2.87 | 15.09% | 13.64% |
TLRY | 1.6B | 602.5M | -17.77% | -52.80% | -2.74 | 2.63 | 18.18% | -18.59% |
CGC | 991.7M | 478.9M | -11.35% | -65.42% | -0.32 | 2.07 | -31.50% | -634.70% |
INVA | 792.9M | 285.2M | -7.22% | -37.95% | 3.6 | 2.78 | -27.21% | -40.28% |
CRON | 768.8M | 114.5M | -15.28% | -37.42% | -4.56 | 6.72 | 27.90% | 57.40% |
ACRS | 541.5M | 29.8M | -40.95% | -47.43% | -6.23 | 18.2 | 340.05% | 4.35% |
OCUL | 400.7M | 51.5M | -2.49% | -0.39% | -5.64 | 7.78 | 18.32% | -984.05% |
ENDP | 94.1M | 2.3B | -43.99% | -88.43% | -0.03 | 0.04 | -22.53% | -376.66% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -1.4% | 14,925,000,000 | 15,142,000,000 | 15,434,000,000 | 15,558,000,000 | 15,878,000,000 |
Gross Profit | -3.9% | 6,973,000,000 | 7,253,000,000 | 7,378,000,000 | 7,457,000,000 | 7,594,000,000 |
S&GA Expenses | -3.5% | 2,265,000,000 | 2,348,000,000 | 2,406,000,000 | 2,427,000,000 | 2,429,000,000 |
EBITDA | -36.2% | -809,000,000 | -594,000,000 | 1,712,000,000 | 2,879,000,000 | - |
EBITDA Margin | -40.8% | -0.05 | -0.04 | 0.11 | 0.18 | - |
Earnings Before Taxes | -43.2% | -3,065,000,000 | -2,140,000,000 | -1,924,000,000 | -456,000,000 | 658,000,000 |
EBT Margin | -45.3% | -0.21 | -0.14 | -0.12 | -0.03 | 0.04 |
Interest Expenses | 3.8% | 948,000,000 | 913,000,000 | - | - | - |
Net Income | -82.4% | -2,353,000,000 | -1,290,000,000 | -1,054,000,000 | -615,000,000 | 417,000,000 |
Net Income Margin | -85.1% | -0.16 | -0.09 | -0.07 | -0.04 | 0.03 |
Free Cahsflow | 102.7% | 1,042,000,000 | 514,000,000 | 476,000,000 | 585,000,000 | 236,000,000 |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -0.6% | 44,006 | 44,252 | 45,932 | 47,059 | 47,666 |
Current Assets | 5.2% | 12,051 | 11,453 | 12,164 | 12,451 | 12,573 |
Cash Equivalents | 25.9% | 2,801 | 2,225 | 2,058 | 2,175 | 2,165 |
Inventory | -0.7% | 3,833 | 3,859 | 4,049 | 4,012 | 3,818 |
Net PPE | 3.1% | 5,739 | 5,568 | 5,740 | 5,932 | 5,982 |
Goodwill | -4.3% | 17,633 | 18,433 | 18,837 | 19,986 | 20,040 |
Liabilities | 1.7% | 35,315 | 34,734 | 36,103 | 36,799 | 36,422 |
Current Liabilities | -0.6% | 11,469 | 11,534 | 10,996 | 11,613 | 11,027 |
LT Debt, Current | -17.4% | 1,696 | 2,054 | 1,403 | - | - |
Shareholder's Equity | -9.9% | 7,897 | 8,767 | 9,828 | 10,260 | 10,278 |
Retained Earnings | -10.5% | -12,882 | -11,660 | -11,716 | -11,484 | -10,529 |
Additional Paid-In Capital | 0.1% | 27,688 | 27,652 | 27,625 | 27,587 | 27,561 |
Accumulated Depreciation | - | 5,241 | - | - | - | - |
Shares Outstanding | 0.1% | 1,111 | 1,110 | 1,107 | - | - |
Minority Interest | 5.7% | 794 | 751 | 791 | 916 | 966 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 48.2% | 1,590 | 1,073 | 1,059 | 1,154 | 798 |
Share Based Compensation | 2.5% | 124 | 121 | 122 | 112 | 119 |
Cashflow From Investing | -10.6% | 656 | 734 | 875 | 1,176 | 1,523 |
Cashflow From Financing | -16.4% | -1,487 | -1,277 | -2,014 | -1,677 | -2,172 |
100%
91.9%
43.9%
Y-axis is the maximum loss one would have experienced if Teva Pharmaceutical Industries was unfortunately bought at previous high price.
-13.2%
-22.7%
-13.9%
1.1%
FIve years rolling returns for Teva Pharmaceutical Industries.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -71.97 | -968,740 | 449,260 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 16.82 | 36,000 | 148,000 | -% |
2023-02-28 | Voya Investment Management LLC | reduced | -6.3 | 76,553 | 1,384,550 | -% |
2023-02-27 | Parallax Volatility Advisers, L.P. | reduced | -18.26 | -735,056 | 8,905,940 | 0.01% |
2023-02-24 | NATIXIS | new | - | 60,785 | 60,785 | -% |
2023-02-24 | National Pension Service | unchanged | - | 2,818 | 19,772 | -% |
2023-02-21 | MACQUARIE GROUP LTD | added | 17.69 | 97,437 | 393,437 | -% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | reduced | -0.73 | 17,719 | 166,719 | -% |
2023-02-21 | DGS Capital Management, LLC | added | 39.61 | 50,932 | 139,089 | 0.09% |
2023-02-17 | TRUIST FINANCIAL CORP | reduced | -5.16 | 92,358 | 1,378,360 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 13, 2023 | capital research global investors | 10.3% | 114,793,989 | SC 13G/A | |
Feb 11, 2022 | capital research global investors | 12.0% | 132,350,750 | SC 13G/A | |
Feb 16, 2021 | capital research global investors | 11.9% | 130,140,247 | SC 13G/A | |
Feb 03, 2021 | wellington management group llp | 0.03% | 310,793 | SC 13G/A | |
Feb 14, 2020 | capital research global investors | 11.9% | 130,950,677 | SC 13G/A | |
Feb 05, 2020 | franklin resources inc | 1.8% | 19,916,016 | SC 13G/A | |
Jan 28, 2020 | wellington management group llp | 7.43% | 81,123,996 | SC 13G |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | - - | - - | - - | - - | - - |
Current Inflation | 5.96 -32.35% | 6.83 -22.47% | 9.92 12.60% | 12.06 36.89% | 13.99 58.80% |
Very High Inflation | - - | - - | - - | - - | - - |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 09, 2023 | 8-K | Current Report | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-07 | Dethlefs Sven | sold | -547,440 | 9.4279 | -58,066 | evp, north america commercial |
2023-03-07 | Stark David Matthew | sold | -466,445 | 9.4279 | -49,475 | exec. vp chief legal officer |
2023-03-07 | Drape Eric | sold | -44,301 | 9.4279 | -4,699 | executive vp global operations |
2023-03-07 | Daniell Richard | sold | -509,173 | 9.4279 | -54,007 | exec. vp, european commercial |
2023-03-06 | Drape Eric | sold | -15,551 | 9.9309 | -1,566 | executive vp global operations |
2023-03-06 | Dethlefs Sven | sold | -192,213 | 9.9309 | -19,355 | evp, north america commercial |
2023-03-06 | Daniell Richard | sold | -178,776 | 9.9309 | -18,002 | exec. vp, european commercial |
2023-03-06 | Stark David Matthew | sold | -163,770 | 9.9309 | -16,491 | exec. vp chief legal officer |
2023-03-05 | Dethlefs Sven | acquired | - | - | 24,952 | evp, north america commercial |
2023-03-05 | Daniell Richard | acquired | - | - | 22,576 | exec. vp, european commercial |
Consolidated Statements of Income (Loss) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Net revenues | $ 3,595 | $ 3,887 | $ 11,041 | $ 11,778 |
Cost of sales | 1,926 | 2,093 | 5,839 | 6,234 |
Gross profit | 1,669 | 1,794 | 5,203 | 5,544 |
Research and development expenses | 175 | 222 | 628 | 723 |
Selling and marketing expenses | 539 | 597 | 1,716 | 1,798 |
General and administrative expenses | 283 | 291 | 892 | 822 |
Intangible assets impairments | 24 | 21 | 223 | 295 |
Goodwill impairment | 0 | 0 | 745 | 0 |
Other assets impairments, restructuring and other items | 36 | 62 | 282 | 227 |
Legal settlements and loss contingencies | 195 | 3 | 2,048 | 113 |
Other income | (2) | (25) | (88) | (73) |
Operating income (loss) | 419 | 623 | (1,244) | 1,638 |
Financial expenses, net | 252 | 241 | 721 | 805 |
Income (loss) before income taxes | 166 | 382 | (1,964) | 833 |
Income taxes (benefit) | 107 | 76 | (792) | 235 |
Share in (profits) losses of associated companies, net | 1 | 5 | (20) | (9) |
Net income (loss) | 58 | 302 | (1,152) | 608 |
Net income (loss) attributable to non-controlling interests | 3 | 11 | (21) | 32 |
Net income (loss) attributable to Teva | $ 56 | $ 292 | $ (1,132) | $ 576 |
Earnings (loss) per share attributable to ordinary shareholders: | ||||
Basic | $ 0.05 | $ 0.26 | $ (1.02) | $ 0.52 |
Diluted | $ 0.05 | $ 0.26 | $ (1.02) | $ 0.52 |
Weighted average number of shares (in millions): | ||||
Basic | 1,111 | 1,103 | 1,109 | 1,102 |
Diluted | 1,119 | 1,109 | 1,109 | 1,109 |
Consolidated Balance Sheets - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 | ||
---|---|---|---|---|
Current assets: | ||||
Cash and cash equivalents | $ 2,225 | $ 2,165 | ||
Accounts receivables, net of allowance for credit losses of $94 million and $90 million as of September 30, 2022 and December 31, 2021 | 3,730 | 4,529 | ||
Inventories | 3,859 | 3,818 | ||
Prepaid expenses | 1,045 | 1,075 | ||
Other current assets | 579 | 965 | ||
Assets held for sale | 16 | 19 | ||
Total current assets | 11,453 | 12,573 | ||
Deferred income taxes | 1,546 | 596 | ||
Other non-current assets | 438 | 515 | ||
Property, plant and equipment, net | 5,568 | 5,982 | ||
Operating lease right-of-use assets | 422 | 495 | ||
Identifiable intangible assets, net | 6,393 | 7,466 | ||
Goodwill | [1] | 18,433 | 20,040 | |
Total assets | 44,252 | 47,666 | ||
Current liabilities: | ||||
Short-term debt | 2,769 | 1,426 | ||
Sales reserves and allowances | 3,648 | 4,241 | ||
Accounts payables | 1,635 | 1,686 | ||
Employee-related obligations | 496 | 563 | ||
Accrued expenses | 2,041 | 2,208 | ||
Other current liabilities | 945 | 903 | ||
Total current liabilities | 11,534 | 11,027 | ||
Long-term liabilities: | ||||
Deferred income taxes | 503 | 784 | ||
Other taxes and long-term liabilities | 3,846 | 2,578 | ||
Senior notes and loans | 18,497 | 21,617 | ||
Operating lease liabilities | 354 | 416 | ||
Total long-term liabilities | 23,200 | 25,395 | ||
Commitments and contingencies, see note 10 | ||||
Total liabilities | 34,734 | 36,422 | ||
Teva shareholders' equity: | ||||
Ordinary shares of NIS 0.10 par value per share; September 30, 2022 and December 31, 2021: authorized 2,495 million shares; issued 1,216 million shares and 1,209 million shares, respectively. | 57 | 57 | ||
Additional paid-in capital | 27,652 | 27,561 | ||
Accumulated deficit | (11,660) | (10,529) | ||
Accumulated other comprehensive loss | (3,153) | (2,683) | ||
Treasury shares as of September 30, 2022 and December 31, 2021: 106 million ordinary shares | (4,128) | (4,128) | ||
Stockholders' equity attributable to Teva shareholders | 8,767 | 10,278 | ||
Non-controlling interests | 751 | 966 | ||
Total equity | 9,519 | 11,244 | ||
Total liabilities and equity | $ 44,252 | $ 47,666 | ||
|